Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the efficacy of triple therapy with TAK-438,
Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to
triple therapy with Lansoprazole, Amoxicillin and Clarithromycin in H. pylori-positive
patients with scarred gastric or duodenal ulcers.